Exercise Testing Helps Assess ATTR Exercise Testing Helps Assess ATTR
Cardiopulmonary exercise testing may be useful in characterizing distinct patterns of functional impairment in patients with transthyretin amyloidosis.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - March 18, 2024 Category: Cardiology Tags: Cardiology Source Type: news
Cardiac amyloidosis 101: Why early diagnosis and targeted treatment matter
Amyloidosis occurs when the body produces abnormal proteins that bind together to form a substance called amyloid. Amyloids can deposit in any tissue or organ, including the heart, kidneys, liver and nerves. When it occurs in the heart, it's called cardiac amyloidosis. Dr. Martha Grogan, a Mayo Clinic cardiologist and director of the Cardiac Amyloid Clinic at Mayo Clinic in Rochester, Minnesota, explains what cardiac amyloidosis is, why knowing the type of amyloid is key… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - February 21, 2024 Category: Databases & Libraries Source Type: news
Ultromics inks deal with Pfizer to develop AI technology
U.K. software developer Ultromics has entered an agreement with Pfizer to expedite marketing clearance in the U.S. for its AI algorithm for detecting cardiac amyloidosis.
Under the partnership with Pfizer, Ultromics will research and pursue U.S. Food and Drug Administration (FDA) clearance for its EchoGo Amyloidosis algorithm. The software has already received Breakthrough Device designation from the FDA for the detection of cardiac amyloidosis. The algorithm uses deep learning to analyze routine ultrasound scans of the heart (echocardiograms) to detect disease that often goes undetected during standard assessments, Ultro...
Source: AuntMinnie.com Headlines - January 10, 2024 Category: Radiology Authors: AuntMinnie.com staff writers Tags: Industry News Ultrasound Source Type: news
FDA Approves New Agent for Nerve Pain From Rare Inherited Disease
(MedPage Today) -- Eplontersen (Wainua) was approved by the FDA to treat polyneuropathy associated with hereditary transthyretin-mediated amyloidosis (ATTR) in adults, Ionis Pharmaceuticals and AstraZeneca announced on Thursday.
Hereditary ATTR... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - December 22, 2023 Category: American Health Source Type: news
Upstate offers nuclear scan for heart issue once thought rare
Upstate's new chair of Medicine seeks to raise awareness of cardiac amyloidosis (Source: SUNY Upstate Medical)
Source: SUNY Upstate Medical - December 22, 2023 Category: Universities & Medical Training Tags: News Source Type: news
FDA Approves Wainua (eplontersen) for the Treatment of Adults with Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis
U.S. FDA approval based on Phase 3 NEURO-TTRansform results showing Wainua demonstrated consistent and sustained benefit halting neuropathy disease progression and improving neuropathy impairment and quality of life
Additional regulatory reviews... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - December 21, 2023 Category: Drugs & Pharmacology Source Type: news
Colchicine: the good, the bad, the ugly, and how to minimise the risks - Stamp LK, Horsley C, Karu LT, Dalbeth N, Barclay M.
Colchicine has an important role in managing various conditions, including gout, familial Mediterranean fever, amyloidosis, Behcet's syndrome, recurrent pericarditis, and calcium pyrophosphate deposition disease. The adverse effect profile of colchicine is... (Source: SafetyLit)
Source: SafetyLit - December 3, 2023 Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news
Diagnosing Cardiac Amyloidosis: 5 Things to Know Diagnosing Cardiac Amyloidosis: 5 Things to Know
Dr Taylor Lebeis highlights the key aspects of a diagnostic workup for cardiac amyloidosis.American College of Cardiology & Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - November 20, 2023 Category: Cardiology Tags: Cardiology Commentary Source Type: news
Road to RSNA 2023: Molecular Imaging
This is just the third year that RSNA has offered a dedicated track on nuclear medicine and molecular imaging, with eight scientific sessions covering research in prostate cancer imaging, breast cancer, cardiovascular and pulmonary imaging, and more. There will be also 30 educational courses and 14 poster sessions. Notably, this is the first year a scientific session is being offered that covers advances in AI in nuclear medicine. Presentations on PET imaging in prostate cancer – an approach that is witnessing widespread adoption – include an array of studies on prostate-specific membrane antigen (PSMA)-based radiotrac...
Source: AuntMinnie.com Headlines - November 15, 2023 Category: Radiology Authors: Will Morton Tags: 2023 2023 Molecular Imaging Preview Source Type: news
Ultra-early phase scintigraphy detects ATTR cardiac amyloidosis
In this study, the researchers analyzed imaging in four patients with ATTR-CA and four patients with hypertensive cardiomyopathy (non-CA) who underwent dynamic scintigraphic scanning. They reconstructed planar images every minute from three to 20 minutes and then every five minutes from 25 to 60 minutes after injection. The H/CL ratio was assessed on each planar image. The H/CL ratio on the planar images acquired at five minutes post-injection showed a significant difference between ATTR-CA and non-CA patients, according to the findings.Ultra-early phase Tc-99m PYP scintigraphy can detect ATTR-CA with 100% sensitivity a...
Source: AuntMinnie.com Headlines - November 15, 2023 Category: Radiology Authors: Will Morton Tags: 2023 Molecular Imaging Preview Source Type: news
Patisiran Can Preserve Functional Capacity in ATTR Amyloidosis
THURSDAY, Oct. 26, 2023 -- For patients with transthyretin amyloidosis (ATTR amyloidosis), administration of an RNA interference therapeutic agent, patisiran, over 12 months results in preserved functional capacity, according to a study published in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 26, 2023 Category: Pharmaceuticals Source Type: news
FDA Denies Approval for Patisiran in ATTR Cardiomyopathy FDA Denies Approval for Patisiran in ATTR Cardiomyopathy
In a complete response letter, the FDA said the clinical meaningfulness of patisiran ' s effects in cardiomyopathy of ATTR amyloidosis are not established, despite good reviews from an advisory panel.Medscape Medical News (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - October 10, 2023 Category: Internal Medicine Tags: Cardiology News Alert Source Type: news
How Does Lecanemab Work in Alzheimer's? How Does Lecanemab Work in Alzheimer's?
How does lecanemab work in AD? A study suggests it blocks the action of a molecular cascade implicated in amyloidosis.Medscape Medical News (Source: Medscape Psychiatry Headlines)
Source: Medscape Psychiatry Headlines - September 16, 2023 Category: Psychiatry Tags: Neurology & Neurosurgery News Source Type: news
FDA Panel Reluctantly Backs Patisiran for ATTR Cardiomyopathy
(MedPage Today) -- FDA advisors conceded on Wednesday that the benefit-risk balance of patisiran (Onpattro) technically checks out in wild-type or hereditary transthyretin amyloid cardiomyopathy (ATTR-CM, also known as cardiac ATTR amyloidosis... (Source: MedPage Today Nephrology)
Source: MedPage Today Nephrology - September 14, 2023 Category: Urology & Nephrology Source Type: news
Blood Transfusions Linked to Intracerebral Hemorrhage Risk Blood Transfusions Linked to Intracerebral Hemorrhage Risk
An exploratory analysis suggests a transfusion-transmissible agent associated with brain amyloidosis may be associated with some types of spontaneous intracerebral hemorrhage.Medscape Medical News (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - September 13, 2023 Category: Internal Medicine Tags: Neurology & Neurosurgery News Source Type: news
